Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ortec seeks HDE (Humanitarian Device Exemption) for skin product:

This article was originally published in Clinica

Executive Summary

Ortec International is seeking US FDA approval to market its Composite Cultured Skin (CCS) product as a treatment for four critical skin conditions under a Humanitarian Device Exemption (HDE). If the application is approved, the product, composed of a bioengineered bovine collagen matrix seeded with dermal and epidermal cells, will be used to treat patients suffering from epidermolysis bullosa, Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme. The New York-based company expects to receive notification from the FDA within 75 days. An HDE allows companies to market devices for treating conditions that affect less than 4,000 in the US.

You may also be interested in...

FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

Stada Grabs GSK Brands In EU

Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts